Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

41. How do symptoms after rectal cancer surgery affect quality of life: a systematic review

How do symptoms after rectal cancer surgery affect quality of life: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2020 PROSPERO

42. Salvage reirradiation using external beam radiotherapy for local failure in prostate cancer: a systematic review and meta-analysis

Salvage reirradiation using external beam radiotherapy for local failure in prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2020 PROSPERO

43. Real-world effectiveness and safety of drug treatments for metastatic colorectal cancer: a protocol for systematic review and network meta-analysis

Real-world effectiveness and safety of drug treatments for metastatic colorectal cancer: a protocol for systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

44. Quality of patient-reported measurement instruments of quality of life, health-related quality of life, anxiety and depression in testicular cancer patients: a systematic review

Quality of patient-reported measurement instruments of quality of life, health-related quality of life, anxiety and depression in testicular cancer patients: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

45. Long-term outcomes of anastomotic leakage after colon cancer resection: a systematic review and meta-analysis

Long-term outcomes of anastomotic leakage after colon cancer resection: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

46. Living with the risk of cancer: a systematic review of the family psychosocial adjustment

Living with the risk of cancer: a systematic review of the family psychosocial adjustment Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2020 PROSPERO

47. Linking physical activity to breast cancer: a two stage review of physical activity, sex steroid hormones, and breast cancer

Linking physical activity to breast cancer: a two stage review of physical activity, sex steroid hormones, and breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

48. Self-monitoring vs motivational interviewing: motivation techniques in self-directed physical activity to improve adherence in breast cancer survivors: a protocol for a systematic review and meta-analysis

Self-monitoring vs motivational interviewing: motivation techniques in self-directed physical activity to improve adherence in breast cancer survivors: a protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2020 PROSPERO

49. Self-management measures for adults with cancer: protocol for a COSMIN systematic review

Self-management measures for adults with cancer: protocol for a COSMIN systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2020 PROSPERO

50. EANM Guideline/SNMMI Procedure Standard on [18F]Fluciclovine PET/CT for Prostate Cancer Imaging

EANM Guideline/SNMMI Procedure Standard on [18F]Fluciclovine PET/CT for Prostate Cancer Imaging [ 18 F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0 | SpringerLink Advertisement Search Search SpringerLink Search [ 18 F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0 , , , , , , , , , , , & ( 2019 ) 251 Accesses 4 Altmetric Abstract The aim of this guideline is to provide standards (...) for the recommendation, performance, interpretation, and reporting of [ 18 F]Fluciclovine PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of [ 18 F]Fluciclovine PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice. This is a preview of subscription content, to check access. Access options 2. Washburn LC, Sun TT, Byrd B, Hayes RL, Butler TA. 1-aminocyclobutane[11C] carboxylic

2020 Society of Nuclear Medicine and Molecular Imaging

51. Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: SGO and ASRM Evidence-Based Review

Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: SGO and ASRM Evidence-Based Review Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review Lee-mayChen, a StephanieV.Blank, b ElizabethBurton, c KarenGlass, d ElizabethPenick, e andTerriWoodard f,g (...) a UniversityofCaliforniaSanFranciscoHelenDillerFamilyComprehensiveCancerCenter,SanFrancisco,California; b Icahn and Blavatnik Family Women's Health Research Institute, New York, New York; c Abington Hospital-Jefferson Health, Abington, Pennsylvania; d CReATe Fertility Centre, Toronto, Ontario, Canada; e Walter Reed National Military Medical Center, Bethesda, Maryland; f University of Texas MD Anderson Cancer Center, Houston, Texas; g Baylor College of Medicine,Houston,Texas Abstract: Providers who care for women at risk for hereditary gynecologic cancers must consider

2020 Society for Assisted Reproductive Technology

52. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) Full Text available with Trip Pro

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) | Journal for ImmunoTherapy of Cancer | Full Text Advertisement Search Search all BMC articles Search The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (...) , the Society for Immunotherapy of Cancer (SITC) reconvened its Cancer Immunotherapy Guidelines (CIG) Renal Cell Carcinoma Subcommittee and tasked it with generating updated consensus recommendations for the treatment of patients with this disease. Introduction The development of novel immuno-oncology (IO) therapeutics has transformed the treatment paradigm for patients with advanced renal cell carcinoma (aRCC) and altered the role of previous approaches involving antiangiogenic agents targeting

2020 Society for Immunotherapy of Cancer

53. Review: Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review

Review: Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review - Gynecologic Oncology Email/Username: Password: Remember me Search Terms Search (...) within Search Volume 155, Issue 3, Pages 508–514 To read this article in full, please review your options for gaining access at the bottom of the page. Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review x Lee-may Chen Affiliations University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

2020 Society of Gynecologic Oncology

54. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study Patient-reported Outcomes With Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small-Cell Lung Cancer (PACIFIC): A Randomised, Controlled, Phase 3 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed (...) to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Lancet Oncol Actions , 20 (12), 1670-1680 Dec 2019 Patient-reported Outcomes With Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small-Cell Lung Cancer (PACIFIC): A Randomised

2020 EvidenceUpdates

55. Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared with Females without Breast Cancer

Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared with Females without Breast Cancer Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared With Females Without Breast Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other (...) characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Med Actions 2019 Nov 9 [Online ahead of print] Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared With Females Without Breast Cancer , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology. 2

2020 EvidenceUpdates

56. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several (...) than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 38 (2), 115-123 2020 Jan 10 Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

57. Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy (...) -Sensitive Prostate Cancer , , , , , , , , , Affiliations Expand Affiliations 1 University of Wisconsin, Madison, WI. 2 University of California, San Francisco, San Francisco, CA. 3 Johns Hopkins University, Baltimore, MD. PMID: 31644357 DOI: Item in Clipboard Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer Douglas G McNeel et al. J Clin Oncol . 2019 Show details J Clin Oncol Actions

2020 EvidenceUpdates

58. Laparoscopic and robotic hysterectomy in endometrial cancer patients with obesity: a systematic review and meta-analysis of conversions and complications

Laparoscopic and robotic hysterectomy in endometrial cancer patients with obesity: a systematic review and meta-analysis of conversions and complications Laparoscopic and Robotic Hysterectomy in Endometrial Cancer Patients With Obesity: A Systematic Review and Meta-Analysis of Conversions and Complications - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Am J Obstet Gynecol Actions , 221 (5), 410-428.e19 Nov 2019 Laparoscopic and Robotic Hysterectomy in Endometrial Cancer Patients With Obesity: A Systematic Review and Meta-Analysis of Conversions and Complications

2020 EvidenceUpdates

59. Ability of Laparoscopic Gastric Mobilization to Prevent Pulmonary Complications After Open Thoracotomy or Thoracoscopic Esophagectomy for Esophageal Cancer: A Systematic Review and Meta-analysis

Ability of Laparoscopic Gastric Mobilization to Prevent Pulmonary Complications After Open Thoracotomy or Thoracoscopic Esophagectomy for Esophageal Cancer: A Systematic Review and Meta-analysis Ability of Laparoscopic Gastric Mobilization to Prevent Pulmonary Complications After Open Thoracotomy or Thoracoscopic Esophagectomy for Esophageal Cancer: A Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Thoracotomy or Thoracoscopic Esophagectomy for Esophageal Cancer: A Systematic Review and Meta-analysis , , , Affiliations Expand Affiliations 1 Division of Esophageal Surgery, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. 2 Division of Esophageal Surgery, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. y.tsubosa@scchr.jp. PMID: 31722075 DOI: Item in Clipboard Review Ability

2020 EvidenceUpdates

60. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 37 (35), 3401-3411 2019 Dec 10 FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109

2020 EvidenceUpdates